Manage Your Liver
Q:

WHO’s latest Hepatitis strategies are focused on preventing and reducing damage caused by hepatitis, what should hepatitis B and C patients do?

A:

According to the latest data provided by the World Health Organization, there are 400 million people living with hepatitis B and C worldwide; 1.4 million die due to these infections every year and many more become newly infected. [1] In recent years, WHO launched a range of new strategies and guidelines for this serious global problem. In 2014 and 2015, for the first time, WHO introduced countermeasures guidance to countries around the world on hepatitis C and B respectively. In the guidelines, WHO clearly presented a 3-part prevention plan which included (not limited to) the following [2]:

 

  • immunization with the hepatitis A and B vaccines to prevent co-infection from these hepatitis viruses to protect the liver;
  • early and appropriate medical management including antiviral therapy if appropriate; and
  • regular monitoring for early diagnosis of chronic liver disease (including liver cirrhosis and liver cancer)

 

Another document published by WHO – “Prevention and Control of Viral Hepatitis Infection” further states that our goals should be to reduce morbidity and mortality due to viral hepatitis, improve the care of patients with viral hepatitis and improve the support provided by our society to hepatitis patients. [3] This implies that WHO is recommending hepatitis patients to think further; other than just killing the virus, focus should also be put on these aspects: how to avoid the spread of the virus, how to reduce liver damage caused by the virus, how to prevent liver cirrhosis and liver cancer, and how to improve activity and ability to work.

 

In a sense, it also shows that WHO does not consider the effects of current treatment options on viral hepatitis B and C to be ideal. These treatments advocated by various professionals failed to address the hazards of viral hepatitis B and C, prevent new infections, and lower the number of patients, or the number of deaths caused by the disease. However, countries around the world have paid a very high price because of these ineffective methods.

 

For now, the general consensus is that our focus should be put on: preventing new infections and reducing the spread of the virus, advocating and seeking ways to reduce inflammation and damage caused by hepatitis, preventing inflammation in the liver to reduce risks of liver cirrhosis and liver cancer, and improving the everyday ability and life skills of hepatitis patients.

 

In this context, our liver health maintenance methods that we advocate and promote are very much in line with the proposal and conclusions by WHO.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis BHepatitis CViral Hepatitis Hep BHep C WHO
Related Questions
A:
In our last post, we brought up the recent findings on extreme liver cancer growth after successful DAA treatment. We are talking about liver cancer of a few centimetres developed within weeks of successful Hep C treatment. These findings are also observed in patients of Gastroenterology. Dr. Roushdi Khalf allah sai
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us